Crucell N.V. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
- Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – GlobalData’s summarization of the company’s business strategy. - SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the company. - Major products and services – A list of major products, services and brands of the company. - Key competitors – A list of key competitors to the company. - Key employees – A list of the key executives of the company. - Executive biographies – A brief summary of the executives’ employment history. - Key operational heads – A list of personnel heading key departments/functions. - Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details. - Key manufacturing facilities – A list of key manufacturing facilities of the company.
Crucell N.V. (Crucell) is a biopharmaceutical company. It discovers, develops, manufactures and markets vaccines and antibodies indicated against infectious diseases. Its product portfolio comprises marketed products, vaccines under development and development stage antibodies. The company’s range of marketed vaccine is targeted towards paediatric, respiratory and travel or endemic infections. Its research and development pipeline consists of vaccines evaluated for treatment against ebola and marburg, HIV, cell based influenza, universal influenza, human papilloma virus (HPV) and respiratory syncytial virus (RSV). The company's products are developed using its proprietary technology platforms. It has operations in China, the Netherlands, Switzerland, Italy, Spain, the UK, Korea, Sweden and the US. Crucell is a part of Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson and is headquartered in Leiden, the Netherlands.
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs. - Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy. - Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company. - Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
Table Of Contents
Crucell N.V. - Strategic SWOT Analysis Review Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Section 1 - About the Company 5 Crucell N.V. - Key Facts 5 Crucell N.V. - Key Employees 6 Crucell N.V. - Major Products and Services 7 Crucell N.V. - Pharmaceutical Pipeline Products Data 8 Crucell N.V., Pipeline Products by Therapy Area 8 Crucell N.V., Pipeline Products by Development Phase 9 Crucell N.V. - History 11 Crucell N.V. - Company Statement 14 Crucell N.V. - Locations And Subsidiaries 15 Head Office 15 Other Locations and Subsidiaries 15 Section 2 - Company Analysis 17 Crucell N.V. - Business Description 17 Crucell N.V. - Corporate Strategy 18 Crucell N.V. - SWOT Analysis 19 SWOT Analysis - Overview 19 Crucell N.V. - Strengths 19 Strength - Focused Research Activities 19 Strength - Global Presence 19 Strength - Proprietary and Novel Technology Platforms 19 Crucell N.V. - Weaknesses 20 Weakness - Limited Number of Products and Customers 20 Crucell N.V. - Opportunities 21 Opportunity - Growing Incidence of Infectious Diseases 21 Opportunity - Promising Product Pipeline 21 Opportunity - Strategic Partnerships 21 Crucell N.V. - Threats 22 Threat - Intense Competition 22 Threat - Government Regulations 22 Threat - Uncertain RandD Outcomes 22 Crucell N.V. - Key Competitors 23 Section 3 - Company's Lifesciences Financial Deals and Alliances 24 Crucell N.V., Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 24 Crucell N.V., Pharmaceuticals and Healthcare, Deals By Type, 2009 to YTD 2015 25 Crucell N.V., Recent Deals Summary 26 Section 4 - Appendix 27 Methodology 27 About GlobalData 27 Contact Us 27 Disclaimer 27
List of Tables
Crucell N.V., Key Facts 5 Crucell N.V., Key Employees 6 Crucell N.V., Major Products and Services 7 Crucell N.V., Number of Pipeline Products by Therapy Area 8 Crucell N.V., Number of Pipeline Products by Development Stage 9 Crucell N.V., Pipeline Products By Therapy Area and Development Phase 10 Crucell N.V., History 11 Crucell N.V., Other Locations 15 Crucell N.V., Subsidiaries 15 Crucell N.V., Key Competitors 23 Crucell N.V., Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 24 Crucell N.V., Pharmaceuticals and Healthcare, Deals By Type, 2009 to YTD 2015 25 Crucell N.V., Recent Deals Summary 26
List of Figures
Crucell N.V., Pipeline Products by Therapy Area 8 Crucell N.V., Pipeline Products by Development Phase 9 Crucell N.V., Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 24 Crucell N.V., Pharmaceuticals and Healthcare, Deals by Type, 2009 to YTD 2015 25